PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business

FDA clearance of the IND for OcuRing™-K enables a U.S. multi-center Phase II cataract surgery trial, with patient enrollment expected in H2 2026. The regulatory greenlight reduces near-term clinical risk and supports the company’s development timeline. Overall, this is a modestly positive catalyst, though cash/valuation impact is likely limited until additional clinical/readout milestones emerge.